Table 2.
Odds ratios and 95% confidence intervals (CI) for tamoxifen and raloxifene use according to participant characteristics
| Tamoxifen | Raloxifene | |||
|---|---|---|---|---|
| Unadjusted OR (95% CI) | Adjusted OR (95% CI) a | Unadjusted OR (95% CI) | Adjusted OR (95% CI) a | |
| Race/ethnicity | ||||
| Non-Hispanic White | 1 | 1 | 1 | 1 |
| Other | 1.17 (0.62, 2.22) | 1.30 (0.68, 2.51) | 0.36 (0.22, 0.59) | 0.42 (0.25, 0.70) |
| Education | ||||
| High school or less | 0.52 (0.23, 1.16) | 0.44 (0.18, 1.06) | 0.75 (0.54, 1.02) | 0.73 (0.53, 1.02) |
| Some college | 0.89 (0.56, 1.43) | 0.97 (0.60, 1.57) | 0.69 (0.55, 0.87) | 0.72 (0.57, 0.91) |
| Bachelor’s degree or higher | 1 | 1 | 1 | 1 |
| Hysterectomy before index age | ||||
| No | 1 | 1 | 1 | 1 |
| Yes | 0.59 (0.32, 1.09) | 0.63 (0.33, 1.18) | 0.91 (0.73, 1.14) | 0.98 (0.78, 1.23) |
| Osteoporosis or osteopenia diagnosis before index age | ||||
| No | 1 | 1 | 1 | 1 |
| Yes | 1.35 (0.77, 2.35) | 1.44 (0.82, 2.54) | 2.59 (2.08, 3.23) | 2.50 (1.99, 3.14) |
| Number of first-degree relatives with breast cancer | ||||
| 0 or 1 | 1 | 1 | 1 | 1 |
| 2+ | 2.10 (1.36, 3.26) | 2.26 (1.45, 3.53) | 3.38 (2.75, 4.14) | 3.30 (2.68, 4.06) |
| BCRAT score (%) b, c | ||||
| <1.67 | 0.57 (0.27, 1.19) | 0.59 (0.28, 1.25) | 0.86 (0.44, 1.67) | 0.91 (0.46, 1.78) |
| 1.67–2.99 | 1 | 1 | 1 | 1 |
| 3.00–5.99 | 1.92 (1.16, 3.19) | 2.11 (1.26, 3.55) | 3.02 (2.37, 3.84) | 2.92 (2.29, 3.72) |
| ≥6.00 | 2.58 (1.00, 6.65) | 3.66 (1.36, 9.86) | 4.85 (3.47, 6.78) | 4.91 (3.48, 6.91) |
| Continuous (per 1% increase) | 1.24 (1.07, 1.43) | 1.30 (1.12, 1.51) | 1.29 (1.22, 1.35) | 1.29 (1.23, 1.36) |
a
Adjusted for education, race/ethnicity, number of first-degree relatives with breast cancer, osteoporosis/osteopenia, hysterectomy
b
Adjusted for education, osteoporosis/osteopenia, hysterectomy
c
Information on history of a breast biopsy with atypical hyperplasia, a component of the BCRAT, was categorized as ‘unknown’ in the risk calculation for all women